Article Text
Abstract
Introduction/Background ERAS pathways aim to standardise and optimise perioperative care and modulate postoperative metabolic and inflammatory response linked with adverse outcomes after surgery. Utilization of ERAS protocol has been shown to decrease complications, length of hospital stay and costs.
Benefits of ERAS pathway include shorter length of stay, decreased postoperative pain and need for analgesia, more rapid return of bowel function, decreased complication and readmission rates, and increased patient satisfaction. Implementation of ERAS protocols has not been shown to increase readmission, mortality, or reoperation rates. These benefits have been replicated across the spectrum of gynecologic surgeries, including open and minimally invasive approaches and benign and oncologic surgeries. Implementation of ERAS program requires collaboration from all members of the surgical team. ERAS is a comprehensive program, and data demonstrate success when multiple components are implemented together.
Although ERAS is associated with significant clinical outcome improvements and cost savings in numerous surgical specialties, several opportunities and challenges deserve further discussion.
Methodology We plan a first retrospettive phase using a form with the 20 principals ERAS variable (in pre, intra and post operative).
We are evaluating data of patients surgically treated for gynecological malignancies in 2023 at Ferrero Hospital in Verduno, Italy.
After this first phase we will begin a prospective phase scheduled with periodical updating meeting (each 2 months) of all the ’actors ’ (surgeons, nurses and social-health operators) with esperts in Gynecologic oncology and ERAS protocol. Final analysis using the same form after 12 months of prospective phase testing the goodness of our pathway of improvement.
Results We started the retrospective analys and we are recruiting centers in Italy that want to join us in this challenge.
Conclusion ERAS protocol Is really the standard of care in gynecologic oncology in Italy? Let’s see the current situation and if our proposal can be usefull to improve clinic practice.
Disclosures No.